2024•GastroenterologyRequires access

985 EFFICACY OF MIRIKIZUMAB IN COMPARISON TO USTEKINUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3 VIVID 1 STUDY

Geert D’Haens, Silvio Danese, Bruce E. Sands, Peter Bossuyt, Francis A. Farraye, Marc Ferrante, Tadakazu Hisamatsu, Arthur Kaser, Jarosław Kierkuś, David Laharie, Walter Reinisch, Britta Siegmund, Sonja M. Bragg, Emily Hon, Zhantao Lin, Michelle Lopes, Nathan Morris, Marijana Protić, Vipul Jairath

Open publisher page 2 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Ustekinumab, Crohn's disease, Medicine, Internal medicine, Gastroenterology, Disease, Dermatology, Adalimumab